YTHDF1's Regulatory Involvement in Breast Cancer Prognosis, Immunity, and the ceRNA Network

Wenting Luo,Youjia Zhou,Jiayang Wang,Keqin Wang,Qing Lin,Yuqiu Li,Yujie Xie,Miao Li,Jie Wang,Lixia Xiong

DOI: https://doi.org/10.3390/ijms25031879

IF: 5.6

2024-02-05

International Journal of Molecular Sciences

Abstract:YTH N6-methyladenosine RNA binding protein 1 (YTHDF1), an m6A reader, has a role in the development and progression of breast cancer as well as the immunological microenvironment. The networks of competing endogenous RNA in cancer have received much attention in research. In tumor gene therapy, the regulatory networks of m6A and competing endogenous RNA are increasingly emerging as a new route. We evaluated the relationship between the YTHDF1 expression, overall survival, and clinicopathology of breast cancer using TCGA, PrognoScan, and other datasets. We used Western blot to demonstrate that YTHDF1 is substantially expressed in breast cancer tissues. Furthermore, we explored YTHDF1′s functions in the tumor mutational burden, microsatellite instability, and tumor microenvironment. Our findings indicate that YTHDF1 is a critical component of the m6A regulatory proteins in breast cancer and may have a particular function in the immunological microenvironment. Crucially, we investigated the relationship between YTHDF1 and the associated competitive endogenous RNA regulatory networks, innovatively creating three such networks (Dehydrogenase/Reductase 4-Antisense RNA 1-miR-378g-YTHDF1, HLA Complex Group 9-miR-378g-YTHDF1, Taurine Up-regulated 1-miR-378g-YTHDF1). Furthermore, we showed that miR-378g could inhibit the expression of YTHDF1, and that miR-378g/YTHDF1 could impact MDA-MB-231 proliferation. We speculate that YTHDF1 may serve as a biomarker for poor prognosis and differential diagnosis, impact the growth of breast cancer cells via the ceRNA network axis, and be a target for immunotherapy against breast cancer.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the regulatory role of YTHDF1 in breast cancer prognosis, immune response, and the competing endogenous RNA (ceRNA) network. Specifically:

1. **The relationship between the expression of YTHDF1 and breast cancer prognosis**: By analyzing data in databases such as TCGA and PrognoScan, researchers evaluated the relationship between the expression level of YTHDF1 and the overall survival rate and clinicopathological features of breast cancer patients. The results showed that YTHDF1 was significantly highly expressed in breast cancer tissues, and its high expression was associated with a poorer prognosis for patients.

2. **The role of YTHDF1 in the tumor microenvironment**: The study further explored the functions of YTHDF1 in tumor mutational burden (TMB), microsatellite instability (MSI), and the tumor microenvironment. It was found that YTHDF1 may play an important role in the tumor - immune microenvironment and affect the infiltration of immune cells.

3. **The relationship between YTHDF1 and the ceRNA network**: Researchers constructed three ceRNA networks related to YTHDF1 (DHRS4 - AS1 - miR - 378g - YTHDF1, HCG9 - miR - 378g - YTHDF1, TUG1 - miR - 378g - YTHDF1) and verified that miR - 378g could inhibit the expression of YTHDF1, thereby affecting the proliferation of MDA - MB - 231 cells.

4. **Potential biomarkers and therapeutic targets**: The study speculated that YTHDF1 may serve as a biomarker for poor prognosis in breast cancer and affect the growth of breast cancer cells through the ceRNA network axis, thus becoming a potential target for breast cancer immunotherapy.

In conclusion, this paper aims to comprehensively analyze the biological functions of YTHDF1 in breast cancer and its roles in immunoregulation and the ceRNA network, providing new ideas for the diagnosis and treatment of breast cancer.